258 related articles for article (PubMed ID: 20829140)
1. [Interest of mycophenolate mofetil in children with membranous lupus nephritis].
Gargah T; Goucha-Louzir R; Lakhoua MR
Nephrol Ther; 2010 Dec; 6(7):564-8. PubMed ID: 20829140
[TBL] [Abstract][Full Text] [Related]
2. Lupus nephritis: treatment with mycophenolate mofetil.
Kapitsinou PP; Boletis JN; Skopouli FN; Boki KA; Moutsopoulos HM
Rheumatology (Oxford); 2004 Mar; 43(3):377-80. PubMed ID: 14963204
[TBL] [Abstract][Full Text] [Related]
3. Mycophenolate mofetil for remission induction in severe lupus nephritis.
Cross J; Dwomoa A; Andrews P; Burns A; Gordon C; Main J; Mathieson P; O'Donoghue D; Jayne D;
Nephron Clin Pract; 2005; 100(3):c92-100. PubMed ID: 15824513
[TBL] [Abstract][Full Text] [Related]
4. A prospective multicentre study of mycophenolate mofetil combined with prednisolone as induction therapy in 213 patients with active lupus nephritis.
F L; Y T; X P; L W; H W; Z S; H Z; Z H;
Lupus; 2008 Jul; 17(7):622-9. PubMed ID: 18625634
[TBL] [Abstract][Full Text] [Related]
5. Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide.
Contreras G; Tozman E; Nahar N; Metz D
Lupus; 2005; 14 Suppl 1():s33-8. PubMed ID: 15803929
[TBL] [Abstract][Full Text] [Related]
6. Mycophenolate mofetil versus azathioprine in the maintenance therapy of lupus nephritis.
Sahin GM; Sahin S; Kiziltas S; Masatlioglu S; Oguz F; Ergin H
Ren Fail; 2008; 30(9):865-9. PubMed ID: 18925525
[TBL] [Abstract][Full Text] [Related]
7. Mycophenolate mofetil as the primary treatment of membranous lupus nephritis with and without concurrent proliferative disease: a retrospective study of 29 cases.
Kasitanon N; Petri M; Haas M; Magder LS; Fine DM
Lupus; 2008 Jan; 17(1):40-5. PubMed ID: 18089682
[TBL] [Abstract][Full Text] [Related]
8. Sequential therapies for proliferative lupus nephritis.
Contreras G; Pardo V; Leclercq B; Lenz O; Tozman E; O'Nan P; Roth D
N Engl J Med; 2004 Mar; 350(10):971-80. PubMed ID: 14999109
[TBL] [Abstract][Full Text] [Related]
9. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis.
Ginzler EM; Dooley MA; Aranow C; Kim MY; Buyon J; Merrill JT; Petri M; Gilkeson GS; Wallace DJ; Weisman MH; Appel GB
N Engl J Med; 2005 Nov; 353(21):2219-28. PubMed ID: 16306519
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group.
Chan TM; Li FK; Tang CS; Wong RW; Fang GX; Ji YL; Lau CS; Wong AK; Tong MK; Chan KW; Lai KN
N Engl J Med; 2000 Oct; 343(16):1156-62. PubMed ID: 11036121
[TBL] [Abstract][Full Text] [Related]
11. Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study.
Boletis JN; Marinaki S; Skalioti C; Lionaki SS; Iniotaki A; Sfikakis PP
Nephrol Dial Transplant; 2009 Jul; 24(7):2157-60. PubMed ID: 19179411
[TBL] [Abstract][Full Text] [Related]
12. Induction therapy for pediatric focal proliferative lupus nephritis: cyclophosphamide versus mycophenolate mofetil.
Lau KK; Ault BH; Jones DP; Butani L
J Pediatr Health Care; 2008; 22(5):282-8. PubMed ID: 18761229
[TBL] [Abstract][Full Text] [Related]
13. Mycophenolate mofetil in lupus nephritis.
Ginzler EM; Aranow C
Lupus; 2005; 14(1):59-64. PubMed ID: 15732290
[TBL] [Abstract][Full Text] [Related]
14. Mycophenolate mofetil as maintenance therapy for proliferative lupus nephritis: a long-term observational prospective study.
Laskari K; Mavragani CP; Tzioufas AG; Moutsopoulos HM
Arthritis Res Ther; 2010; 12(6):R208. PubMed ID: 21059275
[TBL] [Abstract][Full Text] [Related]
15. Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy.
Karim MY; Pisoni CN; Ferro L; Tungekar MF; Abbs IC; D'Cruz DP; Khamashta MA; Hughes GR
Rheumatology (Oxford); 2005 Oct; 44(10):1317-21. PubMed ID: 16049051
[TBL] [Abstract][Full Text] [Related]
16. Maintenance therapy with mycophenolate mofetil for children with severe lupus nephritis after low-dose intravenous cyclophosphamide regimen.
Fujinaga S; Ohtomo Y; Hara S; Umino D; Someya T; Shimizu T; Kaneko K
Pediatr Nephrol; 2008 Oct; 23(10):1877-82. PubMed ID: 18414900
[TBL] [Abstract][Full Text] [Related]
17. Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS).
Sinclair A; Appel G; Dooley MA; Ginzler E; Isenberg D; Jayne D; Wofsy D; Solomons N
Lupus; 2007; 16(12):972-80. PubMed ID: 18042591
[TBL] [Abstract][Full Text] [Related]
18. Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials.
Henderson LK; Masson P; Craig JC; Roberts MA; Flanc RS; Strippoli GF; Webster AC
Am J Kidney Dis; 2013 Jan; 61(1):74-87. PubMed ID: 23182601
[TBL] [Abstract][Full Text] [Related]
19. Pilot 24 month study to compare mycophenolate mofetil and tacrolimus in the treatment of membranous lupus nephritis with nephrotic syndrome.
Yap DY; Yu X; Chen XM; Lu F; Chen N; Li XW; Tang CS; Chan TM
Nephrology (Carlton); 2012 May; 17(4):352-7. PubMed ID: 22295934
[TBL] [Abstract][Full Text] [Related]
20. Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression.
Mak A; Cheak AA; Tan JY; Su HC; Ho RC; Lau CS
Rheumatology (Oxford); 2009 Aug; 48(8):944-52. PubMed ID: 19494179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
